Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials
María Eugenia-Toledo-Romaní, Leslyhana Verdecia-Sánchez, Meiby Rodríguez-González, et al.
Vaccine (2022) Vol. 40, Iss. 31, pp. 4220-4230
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Protein subunit vaccines: Promising frontiers against COVID-19
Vivek P. Chavda, Eswara Naga Hanuma Kumar Ghali, Pankti C. Balar, et al.
Journal of Controlled Release (2024) Vol. 366, pp. 761-782
Closed Access | Times Cited: 15
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial
María Eugenia Toledo-Romaní, Mayra García-Carmenate, Carmen Valenzuela‐Silva, et al.
The Lancet Regional Health - Americas (2022) Vol. 18, pp. 100423-100423
Open Access | Times Cited: 39
The role of vaccines in the COVID-19 pandemic: what have we learned?
Florian Krammer
Seminars in Immunopathology (2023) Vol. 45, Iss. 4-6, pp. 451-468
Open Access | Times Cited: 38
Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine
Ehsan Mostafavi, Sana Eybpoosh, Mohammad Karamouzian, et al.
JAMA Network Open (2023) Vol. 6, Iss. 5, pp. e2310302-e2310302
Open Access | Times Cited: 21
COVID-19 Vaccines over Three Years after the Outbreak of the COVID-19 Epidemic
Aleksandra Anna Zasada, Aniela Darlińska, Aldona Wiatrzyk, et al.
Viruses (2023) Vol. 15, Iss. 9, pp. 1786-1786
Open Access | Times Cited: 19
A comprehensive review on immunogen and immune-response proteins of SARS-CoV-2 and their applications in prevention, diagnosis, and treatment of COVID-19
Daohong Zhang, Deepak Kukkar, Ki‐Hyun Kim, et al.
International Journal of Biological Macromolecules (2024) Vol. 259, pp. 129284-129284
Closed Access | Times Cited: 6
COVID-19 vaccines: A comprehensive review of safety and efficacy
Zhipeng Yan, Ming Yang, Ching‐Lung Lai
Elsevier eBooks (2025), pp. 685-777
Closed Access
Comparative Analysis of SARS-CoV-2 Antibody Responses across Global and Lesser-Studied Vaccines
José Víctor Zambrana, Carlos Saenz, Hannah E. Maier, et al.
Vaccines (2024) Vol. 12, Iss. 3, pp. 326-326
Open Access | Times Cited: 4
CHO cells for virus-like particle and subunit vaccine manufacturing
Zalma V. Sanchez-Martinez, Sergio P. Alpuche-Lazcano, Matthew Stuible, et al.
Vaccine (2024) Vol. 42, Iss. 10, pp. 2530-2542
Open Access | Times Cited: 4
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children
Rinaldo Puga-Gómez, Yariset Ricardo-Delgado, Chaumey Rojas-Iriarte, et al.
International Journal of Infectious Diseases (2022) Vol. 126, pp. 164-173
Open Access | Times Cited: 19
Structural and computational design of a SARS-CoV-2 spike antigen with improved expression and immunogenicity
James A. Williams, Marco Biancucci, Laura N. Lessen, et al.
Science Advances (2023) Vol. 9, Iss. 23
Open Access | Times Cited: 11
Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals
Sana Eybpoosh, Alireza Biglari, Rahim Sorouri, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 11, pp. e1011744-e1011744
Open Access | Times Cited: 11
Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2–11 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population study
María Eugenia Toledo-Romaní, Carmen Valenzuela‐Silva, Minerva Montero-Díaz, et al.
The Lancet Regional Health - Americas (2024) Vol. 34, pp. 100750-100750
Open Access | Times Cited: 3
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomised, placebo-controlled phase 3 clinical trial
María Eugenia Toledo-Romaní, Mayra García-Carmenate, Carmen Valenzuela‐Silva, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 20
Reactogenic sleepiness after COVID-19 vaccination. A hypothesis involving orexinergic system linked to inflammatory signals
Bárbara B. Garrido‐Suárez, Mariana Garrido-Valdes, Gabino Garrido
Sleep Medicine (2022) Vol. 98, pp. 79-86
Open Access | Times Cited: 15
COVID-19 vaccines and a perspective on Africa
Alberto Mantovani, María Rescigno, Guido Forni, et al.
Trends in Immunology (2023) Vol. 44, Iss. 3, pp. 172-187
Open Access | Times Cited: 7
Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress
Angelina Kovalenko, Ekaterina M. Ryabchevskaya, Ekaterina A. Evtushenko, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1701-1701
Open Access | Times Cited: 7
Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles
Anthony D. Bai, Yunbo Jiang, David Nguyen, et al.
JAMA Network Open (2023) Vol. 6, Iss. 1, pp. e2253301-e2253301
Open Access | Times Cited: 5
Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response—a prospective, single-arm study
Maryam Barkhordar, Bahram Chahardouli, Alireza Biglari, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Studying SARS-CoV-2 interactions using phage-displayed receptor binding domain as a model protein
Beatriz Pérez-Massón, Yazmina Quintana-Pérez, Yaima Tundidor, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial
Leyla Sharifi Aliabadi, Manoochehr Karami, Maryam Barkhordar, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3
Safety and Efficacy of the Two Doses Conjugated Protein-Based SOBERANA-02 COVID-19 Vaccine and of a Heterologous Three-Dose Combination with SOBERANA-PLUS: Double-Blind, Randomised, Placebo-Controlled Phase 3 Clinical Trial
María Eugenia-Toledo-Romaní, Mayra García Carmenate, Carmen Valenzuela‐Silva, et al.
SSRN Electronic Journal (2022)
Open Access | Times Cited: 5
Evaluation of Safety and Immunogenicity of a Recombinant Receptor-Binding Domain (RBD)-Tetanus Toxoid (TT) Conjugated SARS-CoV-2 Vaccine (PastoCovac) in Recipients of Autologous Hematopoietic Stem Cell Transplantation Compared to the Healthy Controls; A Prospective, Open-Label Clinical Trial
Maryam Barkhordar, Mohammad Ahmadvand, Leyla Sharifi Aliabadi, et al.
Vaccines (2023) Vol. 11, Iss. 1, pp. 117-117
Open Access | Times Cited: 2
Comparative Immune Response after Vaccination with SOBERANA® 02 and SOBERANA® plus Heterologous Scheme and Natural Infection in Young Children
Rocmira Pérez-Nicado, Chiara Massa, Laura Rodríguez-Noda, et al.
Vaccines (2023) Vol. 11, Iss. 11, pp. 1636-1636
Open Access | Times Cited: 2
Potential Protectivity of a Conjugated COVID-19 Vaccine against Tetanus
Delaram Doroud, Fatemeh Ashrafian, Amir Javadi, et al.
Vaccines (2024) Vol. 12, Iss. 3, pp. 243-243
Open Access
Page 1 - Next Page

Scroll to top